Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Tag: heart failure


Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

November 17th 2020

In patients with diabetes and recent worsening heart failure, sotagliflozin therapy, initiated before or shortly after discharge, resulted in a significantly lower total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure than placebo (NEJM)

Categories: Cardiovascular, Medication, News
Tags: heart failure, sotagliflozin

Categories: Cardiovascular, Medication
Tags: heart failure, sotagliflozin

Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients

May 31st 2020

Use of SGLT2i improved cardiac function in diabetic patients, regardless of the presence of HF. The improvements were more prominent in HF patients, especially in those with HFrEF. These improvements in cardiac function would contribute to the clinical benefit of SGLT2i (Cardiovascular Diabetology)

Categories: Medication, News
Tags: heart failure, SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: heart failure, SGLT2 inhibitors, Type 2 Diabetes

12‐Year Trends in Pharmacologic Treatment of Type 2 Diabetes among Patients with Heart Failure in the United States

January 6th 2020

Despite their promising cardiovascular safety profile, SGLT‐2i use remains relatively limited (Diabetes, Obesity and Metabolism)

Categories: News
Tags: heart failure, Type 2 Diabetes

Categories:
Tags: heart failure, Type 2 Diabetes

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

November 21st 2019

Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than among those who received placebo, regardless of the presence or absence of diabetes (NEJM)

Categories: Medication, News
Tags: dapagliflozin, heart failure

Categories: Medication
Tags: dapagliflozin, heart failure

Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) Reduce Hospitalization for Heart Failure Only and Have No Effect on Atherosclerotic Cardiovascular Events: A Meta-Analysis

March 14th 2019

The predominant impact of SGLT-2i is on “hHF or CV mortality” composite driven predominantly by reduction in hHF and not atherosclerotic CV disease (Diabetes Therapy)

Categories: Medication, News
Tags: heart failure, SGLT2 inhibitors

Categories: Medication
Tags: heart failure, SGLT2 inhibitors

Heart failure among people with Type 2 diabetes mellitus: real‐world data of 289 954 people from a diabetes database

February 4th 2019

Heart failure is common in diabetes mellitus, but the prevalence in the DPV is lower frequent than expected. The reason for improved metabolic control in heart failure may be intensified therapy with insulin, lipid‐lowering medication and anti‐hypertensives in this cohort (Diabetic Medicine)

Categories: Cardiovascular, News
Tags: heart failure, insulin, Type 2 Diabetes

Categories: Cardiovascular
Tags: heart failure, insulin, Type 2 Diabetes

Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus

June 25th 2018

This study helps further characterize the potential benefits and harms of SGLT2i in routine clinical practice to complement evidence from clinical trials and prior observational studies (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: heart failure, SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: heart failure, SGLT2 inhibitors, Type 2 Diabetes

Exploration of the clinical benefits of sodium glucose co-transporter 2 inhibitors in diabetic patients with concomitant heart failure

May 25th 2018

The beneficial effects of SGLT2 inhibitors on such outcomes and the heart itself are unique characteristics among antidiabetic agents, and SGLT2 inhibitors are expected to be a promising therapeutic option for CV disease and HF care (Cardiovascular Diabetology)

Categories: Cardiovascular, News
Tags: heart failure, SGLT2 inhibitors

Categories: Cardiovascular
Tags: heart failure, SGLT2 inhibitors

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial

September 2nd 2017

In patients with T2D and established CVD, a sizeable proportion without HF at baseline are at high or very high risk for HF outcomes, indicating the need for active case finding in this patient population. Empagliflozin consistently improved HF outcomes both in patients at low or high HF risk (European Heart Journal)

Categories: Cardiovascular, News
Tags: Empagliflozin, heart failure

Categories: Cardiovascular
Tags: Empagliflozin, heart failure

Cardiac Stress and Inflammatory Markers as Predictors of Heart Failure in Patients With Type 2 Diabetes: The ADVANCE Trial

August 23rd 2017

Only NT-proBNP strongly and consistently improved the prediction of heart failure in patients with type 2 diabetes beyond a wide range of clinical risk factors and biomarkers (Diabetes Care)

Categories: Cardiovascular, News
Tags: heart failure, prediction, Type 2 Diabetes

Categories: Cardiovascular
Tags: heart failure, prediction, Type 2 Diabetes

Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study

May 25th 2017

Predominantly male patients initiating treatment for diabetes mellitus with sulfonylurea had a higher risk of heart failure and cardiovascular death compared to similar patients initiating metformin (Journal of the American Academy of Heart Association)

Categories: Medication, News
Tags: heart failure, metformin, sulfonylureas

Categories: Medication
Tags: heart failure, metformin, sulfonylureas

Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus

April 14th 2016

Sitagliptin use does not affect the risk for hHF in T2DM, both overall and among high-risk patient subgroups (JAMA Cardiology)

Categories: Medication, News
Tags: heart failure, sitagliptin

Categories: Medication
Tags: heart failure, sitagliptin

Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes

January 9th 2016

In patients with type 2 diabetes, there was no association between hHF, or other selected cardiovascular outcomes, and treatment with a DPP-4i relative to SU or treatment with saxagliptin relative to sitagliptin (Diabetes Care)

Categories: Cardiovascular, News
Tags: DPP-4i, heart failure, Type 2 Diabetes

Categories: Cardiovascular
Tags: DPP-4i, heart failure, Type 2 Diabetes

Intensity of statin therapy and new hospitalizations for heart failure in patients with type 2 diabetes

October 29th 2015

In type 2 diabetes, moderate-intensity statins, in comparison to low-intensity or no statin, were associated with lower HF incidence independently of LDL levels or of CAD events (BMJ)

Categories: Cardiovascular, News
Tags: heart failure, statin

Categories: Cardiovascular
Tags: heart failure, statin

Risk of new-onset heart failure in patients using sitagliptin: a population-based cohort study

July 24th 2015

In our sample of patients who are at high risk of heart failure after acute coronary syndrome, sitagliptin exposure was not associated with an increased risk of de novo heart failure (Diabetic Medicine)

Categories: Medication, News
Tags: heart failure, sitagliptin

Categories: Medication
Tags: heart failure, sitagliptin

Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials

March 25th 2015

Compared with standard care, glycaemic lowering by various drugs or strategies might increase the risk of heart failure, with the magnitude of risk dependent on the method of glucose lowering and, potentially, weight gain (The Lancet Diabetes & Endocrinology)

Categories: Cardiovascular, News
Tags: heart failure

Categories: Cardiovascular
Tags: heart failure

Both High and Low HbA1c Predict Incident Heart Failure in Type 2 Diabetes Mellitus

March 19th 2015

Both high and low HbA1c predicted heart failure development in our cohort, forming a U-shaped relationship (Circulation: Heart Failure)

Categories: Monitoring, News
Tags: HbA1c, heart failure

Categories: Monitoring
Tags: HbA1c, heart failure

Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials

March 17th 2015

Compared with standard care, glycaemic lowering by various drugs or strategies might increase the risk of heart failure, with the magnitude of risk dependent on the method of glucose lowering and, potentially, weight gain (The Lancet Diabetes & Endocrinology)

Categories: News, Treatment
Tags: heart failure

Categories: Treatment
Tags: heart failure

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

AstraZenecaNapp DiabetesNovo Nordisk

Silver Sponsors

Abbott Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)About Ascensia Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 elderly Empagliflozin exenatide GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis lada liraglutide metformin microvascular mortality NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes USA Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership